Advertisement

PROCEPT BioRobotics Corporation PRCT

Set alert

Price alert · PRCT

All alert types
19.20 USD -1.10 -5.42%

At close · Oct 30

19.20 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
19.17 × 2
Ask
19.18 × 2
18.90 Day range 20.37
16.69 52-week range 36.10
YTD
-38.97%
1 year
-44.15%
Open
20.33
Prev close
20.30
Mkt cap
1.10B
Vol
856.46K
Avg vol
1.35M
EPS
-1.94
P/E
0.00
Div yield
0.00%
More statistics
Low
18.90
High
20.37
Forward P/E
-16.38
Beta
0.92
Short ratio
5.27
Inst. own
97.75%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
19.43
200-d avg
23.38
1y target
22.25

3M chart

Chart tools
Interval
PRCT three-month price chart16.718.319.821.422.9Jul 31Aug 19Sep 8Sep 24Oct 13Oct 30

Key statistics

Market cap
1.10B
Enterprise value
1.01B
Trailing P/E
0.00
Forward P/E
-16.38
PEG ratio
0.00
Price / sales
3.26
Price / book
3.23
EPS (TTM)
-1.94
Beta
0.92
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-32.53%
Revenue (TTM)
337.34M
Revenue growth
19.30%
Free cash flow
-48.97M
Total cash
227.91M
Total debt
77.50M
Return on equity
-30.24%
Shares outstanding
57.27M
Short % of float
13.48%
50-day average
19.43
200-day average
23.38

Analyst view

Consensus: hold

Hold
Price target (mean) 22.25 +15.9% upside
Target (low)
16.00
Target (mean)
22.25
Target (high)
30.00
Ratings (0m) 15 5 buy · 9 hold · 1 sell
  • Strong buy2
  • Buy3
  • Hold9
  • Sell0
  • Strong sell1

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate -0.38935.

Earnings history

Financials — quick view

All financials
PRCT Revenue — quarterly 94.50M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PRCT Net income — quarterly -26.86M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PRCT EPS — quarterly -0.47
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

PRCT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 2026-0.38952———
Aug 4, 2026Jun 30, 2026-0.46186-0.47-0.01-1.76%
Apr 29, 2026Mar 31, 2026-0.55-0.56-0.01-1.82%
Feb 25, 2026Dec 31, 2025-0.32-0.53-0.21-65.62%
Nov 4, 2025Sep 30, 2025-0.41-0.38+0.03+7.32%
Aug 6, 2025Jun 30, 2025-0.41-0.35+0.06+14.63%

Upgrades / downgrades

PRCT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 7, 2026Barclaysinit—Overweight
Aug 5, 2026TD CowenmainBuyBuy
Aug 5, 2026Piper SandlermainOverweightOverweight
Aug 5, 2026Evercore ISI GroupmainOutperformOutperform
Aug 5, 2026William BlairdownOutperformMarket Perform
Jul 6, 2026Truist SecuritiesdownBuyHold

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on PRCT — it syncs with the Stock Master app.

Insider holders

PRCT insider holders
InsiderRelationLatest transactionDateShares held
DESAI ANTAL ROHITDirectorStock Award(Grant)Jun 8, 202638,467
HARRIS TAYLOR CDirectorStock Award(Grant)Jun 8, 2026102,491
MOLL FREDERIC HDirectorStock Award(Grant)Jun 8, 2026866,474
NOURI ALALEHOfficerSaleSep 8, 2026127,737
SHARMA POOJAOfficerStock Award(Grant)Aug 12, 2026111,181
SHIBLAQ HISHAMOfficerConversion of Exercise of derivative securityJun 5, 202563,133

Institution ownership

PRCT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.50%4,869,82893.50MJun 29, 2026
T. Rowe Price Investment Management, Inc.5.70%3,265,70462.70MJun 29, 2026
BNP Paribas Asset Management Holding S.A.4.93%2,823,84954.22MJun 29, 2026
Vanguard Portfolio Management LLC4.41%2,526,80248.51MJun 29, 2026
Vanguard Capital Management LLC4.30%2,460,80247.25MJun 29, 2026
State Street Corporation2.82%1,617,47531.06MJun 29, 2026

Fund ownership

PRCT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.98%1,708,16432.80MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.53%1,448,09627.80MSep 29, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.2.30%1,318,12025.31MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.16%1,239,15023.79MJun 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Venture Fund1.55%890,50917.10MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.24%711,29913.66MJun 29, 2026
Advertisement